Investment to support RNA therapeutics for epilepsy and neurological disorders Angelini Ventures has co-led a €20 million ...

Novartis has announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) achieved the primary ...

Kearney Urology Center has reported a 50% reduction in biopsies since adopting EpiSwitch PSE, a new accurate blood test for ...

M-Trust set to improve product safety and counterfeiting solutions Merck has launched the beta version of M-Trust, a ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved Rybrevant ...

Sequana Medical NV has announced the US FDA approval of its Alfapump system for treating recurrent or refractory ascites due to liver cirrhosis. This approval marks Alfapump as the first active ...

Matthew Taylor, chief executive of the NHS Confederation, stated, “This announcement sets out a range of welcome commitments – not just the commission but also short-term support for the sector as ...

MindMed has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically optimised form of lysergide D-tartrate (LSD) for treating Generalised Anxiety ...

Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264, an investigational oral selective SOS1 inhibitor, to assess its safety ...